Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Zymeworks, Inc. is currently managing 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are handled by 6 distinct examiners, which indicates a high level of diversification among the USPTO staff reviewing the company's applications. The workload is distributed across 4 distinct art units, suggesting that while the examiners are unique, some applications share similar technical classifications. This structure requires a strategy that balances individual examiner preferences with the broader standards of the 4 art units.
The busiest examiner, HUYNH, PHUONG N, is responsible for 1 pending office action. This demonstrates that the 6 total pending actions are spread evenly across the 6 examiners, with no single official managing more than one case. With 1 busiest examiner pending action, the company must maintain active communication with six different individuals. This broad distribution across 4 art units requires a robust management strategy to ensure consistency in technical arguments while addressing the specific preferences of each distinct examiner. Practitioners should track the 6 distinct examiners to optimize the prosecution timeline for this biotechnology portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (40%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUYNH, PHUONG N | 1 | 65.8% | +53.6% |
| EDGINGTONGIORDANO, FRANCESCA | 1 | 71.8% | +29.4% |
| HOLTZMAN, KATHERINE ANN | 1 | 64.8% | +59.4% |
| DUNN, LINDSAY MICHELLE | 1 | 80.0% | +0.0% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258057 | STABILIZED TCR CONSTRUCTS AND METHODS OF USE | DUNN, LINDSAY MICHELLE | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18612960 | Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs | HUYNH, PHUONG N | 238d overdue |
| 18692278 | METHODS OF TREATING CANCER WITH ANTI-HER2 BIPARATOPIC ANTIBODIES | EDGINGTONGIORDANO, FRANCESCA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18612960 | Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs | HUYNH, PHUONG N | 238d overdue |
| 18692278 | METHODS OF TREATING CANCER WITH ANTI-HER2 BIPARATOPIC ANTIBODIES | EDGINGTONGIORDANO, FRANCESCA | — |
| 18551851 | CYSTEINE ENGINEERED ANTIBODY CONSTRUCTS, CONJUGATES AND METHODS OF USE | HOLTZMAN, KATHERINE ANN | — |
| 17999477 | IMMUNOGLOBULIN Fc REGION VARIANTS COMPRISING STABILITY-ENHANCING MUTATIONS | BRISTOL, LYNN ANNE | — |
| Art Unit | Apps |
|---|---|
| 1643 | 3 |
| 1641 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18612960 | Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs | HUYNH, PHUONG N | 1641 | §102§112 | Final Rejection | 238d overdue | Pending | Mar 21, 2024 |
| 18692278 | METHODS OF TREATING CANCER WITH ANTI-HER2 BIPARATOPIC ANTIBODIES | EDGINGTONGIORDANO, FRANCESCA | 1643 | §103§112Other | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18551851 | CYSTEINE ENGINEERED ANTIBODY CONSTRUCTS, CONJUGATES AND METHODS OF USE | HOLTZMAN, KATHERINE ANN | 1646 | §112DP | Final Rejection | — | Pending | Sep 21, 2023 |
| 18258057 | STABILIZED TCR CONSTRUCTS AND METHODS OF USE | DUNN, LINDSAY MICHELLE | 1643 | §112 | Non-Final OA | — | Pending | Jun 16, 2023 |
| 17999477 | IMMUNOGLOBULIN Fc REGION VARIANTS COMPRISING STABILITY-ENHANCING MUTATIONS | BRISTOL, LYNN ANNE | 1643 | §112 | Non-Final OA | — | Pending | Nov 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZymeworks, Inc. has 5 pending office actions as of October 2026, spread across 3 art units and 5 examiners.
Phuong N Huynh has the most, with 1 of Zymeworks, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
